Corona Remedies Q4 Results FY26 PAT Jumps 44 Percent Dividend Rs 10 Per Share Pharma Chronic Segments Outperform

Corona Remedies Q4 results FY26 reported quarterly profit after tax jumping 44% year on year for Q4 FY26, continuing the company consistent outperformance versus the Indian Pharmaceutical Market (IPM). The Corona Remedies Q4 results were announced on May 11, 2026, with the board declaring a final dividend of Rs 10 per equity share for FY26.

For full fiscal year FY26, the Corona Remedies Q4 results cap a strong year building on Q2 FY26 PAT of Rs 52.32 crore and H1 FY26 PAT of Rs 98.52 crore. The Corona Remedies Q4 FY26 EBITDA margins have consistently exceeded 21% across FY26. The company acquired Wokadine from Dr. Reddys Laboratories effective March 30, 2026, entering the Rs 648 crore povidone iodine market, and also acquired seven brands from Bayer Zydus for approximately Rs 7.5-8 crore.

Get Free Stock Recommendations on Univest

Corona Remedies Q4 FY26 Results at a Glance

Metric	Q4 FY26	Change / Context
Q4 PAT Growth	Up 44% YoY	Strong quarterly delivery
Final Dividend	Rs 10 per share	FY26 declared
H1 FY26 PAT	Rs 98.52 crore	+35.1% YoY
Q2 FY26 PAT	Rs 52.32 crore	+21.8% YoY
EBITDA Margin FY26	Consistently above 21%	Premium margins
Wokadine Acquisition	From Dr. Reddys, March 2026	Rs 648 crore iodine market

Track live Corona Remedies financials, analyst ratings and peer comparisons on the Univest Screener.

Key Highlights from Corona Remedies Q4 FY26 Results

Chronic Segment Focus Drives Consistent Outperformance

Corona Remedies Q4 results FY26 chronic and semi-chronic therapeutic segments contributing approximately 70% of revenue have consistently outperformed IPM growth. The Corona Remedies Q4 results FY26 revenue has grown 15-17% YoY throughout the year supported by specialist prescription focus. Top brands including B-29 VMN, Myoril, Tricium, Cortel, and Obimet drive approximately 72% of revenue.

Strategic Brand Acquisitions Expand Portfolio

Corona Remedies Q4 results FY26 acquisitions strengthen the brand portfolio: Wokadine from Dr. Reddys enters Rs 648 crore povidone iodine market with effective date March 30, 2026, and Bayer Zydus seven-brand acquisition for approximately Rs 7.5-8 crore adds scale. The Corona Remedies Q4 results FY26 target 15% revenue CAGR and 20% PAT growth over three to four years.

What Drove Corona Remedies Q4 FY26 Performance

Corona Remedies Q4 results were driven by chronic therapy specialist prescriptions, brand portfolio strength in women health, cardiac, diabetes, pain, and urology segments, and strategic brand acquisitions expanding market footprint.

Outlook for FY27 After Corona Remedies Q4 Results

Following Corona Remedies Q4 results FY26, FY27 outlook is positive with Wokadine integration, Bayer Zydus brand ramp-up, and structural India pharma market growth. Company targets 15% revenue CAGR and 20% PAT CAGR over next three to four years.

Conclusion

Corona Remedies Q4 results FY26 delivered Q4 PAT up 44% YoY with final dividend Rs 10 per share. The Corona Remedies Q4 results Wokadine acquisition and consistent 21%+ EBITDA margins confirm premium pharma positioning.

Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

What was Corona Remedies Q4 FY26 PAT growth?

Corona Remedies Q4 results FY26 reported Q4 net profit after tax growing 44% year on year continuing consistent outperformance versus the Indian Pharmaceutical Market (IPM).

What dividend did Corona Remedies declare?

Corona Remedies Q4 board declared final dividend of Rs 10 per equity share for FY26 alongside Corona Remedies Q4 results FY26 announcement.

What is Corona Remedies H1 FY26 performance?

H1 FY26 PAT for Corona Remedies was Rs 98.52 crore up 35.1% YoY on revenue Rs 707.67 crore up 17% as part of the strong FY26 trajectory confirmed in Corona Remedies Q4 results FY26.

What acquisition did Corona Remedies make?

Corona Remedies Q4 results FY26 note acquisition of Wokadine from Dr. Reddys effective March 30 2026 entering Rs 648 crore povidone iodine market and Bayer Zydus seven brands.

What does Corona Remedies do?

Corona Remedies is a domestic branded pharmaceutical company focused on chronic and semi-chronic therapies including women health, cardio-diabetes, pain, and urology as reflected in Corona Remedies Q4 results FY26.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026